0001209191-18-060062.txt : 20181127 0001209191-18-060062.hdr.sgml : 20181127 20181127192108 ACCESSION NUMBER: 0001209191-18-060062 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20181126 FILED AS OF DATE: 20181127 DATE AS OF CHANGE: 20181127 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Smith David V CENTRAL INDEX KEY: 0001229447 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36070 FILM NUMBER: 181203953 MAIL ADDRESS: STREET 1: 6035 STONERIDGE DRIVE CITY: PLEASANTON STATE: CA ZIP: 94588 FORMER NAME: FORMER CONFORMED NAME: SMITH DAVID V DATE OF NAME CHANGE: 20030429 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: FIVE PRIME THERAPEUTICS INC CENTRAL INDEX KEY: 0001175505 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 260038620 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 111 OYSTER POINT BOULEVARD CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 BUSINESS PHONE: 415-365-5600 MAIL ADDRESS: STREET 1: 111 OYSTER POINT BOULEVARD CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2018-11-26 0 0001175505 FIVE PRIME THERAPEUTICS INC FPRX 0001229447 Smith David V 111 OYSTER POINT BOULEVARD SOUTH SAN FRANCISCO CA 94080 0 1 0 0 Executive Vice President & CFO Common Stock 2018-11-26 4 A 0 40000 0.00 A 40000 D Employee Stock Option (right to buy) 12.47 2018-11-26 4 A 0 185000 0.00 A 2028-11-25 Common Stock 185000 185000 D Represents shares of restricted stock, which will vest according to the following schedule: one-third (1/3) of the restricted stock will vest on each of November 26, 2019, 2020 and 2021, provided the reporting person provides services to Five Prime Therapeutics, Inc. (the "Company") through each such date. One fourth (1/4) of the shares underlying this option will vest on November 26, 2019, and the remainder of the shares underlying this option will vest at a rate of one forty-eighth (1/48) per month thereafter, provided the reporting person provides services to the Company through each such date. /s/ Francis Sarena, Attorney-in-fact 2018-11-27